Dysregulation of individual SWI/SNF subunits plays tissue and subunit-specific roles in tumorigenesis, disease progression, and therapeutic resistance. This application will assess the role of the BAF57 SWI/SNF subunit in the context of prostate development and prostate cancer (PCa). In PCa, fatal disease arises as a failure to control androgen receptor (AR) activity, and BAF57 is a known effector of AR. Notably, first line therapy for disseminated PCa relies on AR-directed therapeutics. While initially effective, recurrent, incurable tumors form within 2-3 years. Substantive evidence shows that the incurable, """"""""castration-resistant"""""""" stage (referred to as castration-resistant prostate cancer, CRPC) is driven by resurgent AR activity. Major lines of investigation support the hypothesis that BAF57 deregulation induces alterations in SWI/SNF that support aberrant AR activity and progression to CRPC. This application will challenge the in vivo impact of BAF57 in prostate development and disease: First, we showed that BAF57 binds directly to AR, is recruited to in the presence of androgen to sites of AR function, and promotes androgen- dependent gene expression in a SWI/SNF-reliant manner. These BAF57 functions proved critical, as ablation of BAF57-AR interaction nullified ligand-dependent AR activity. Parallel studies showed that even modest changes in SWI/SNF subunit expression can have potent effects on SWI/SNF function, molecular output, and cellular phenotypes. Thus, our data underscore the importance of delineating the precise role of BAF57 in SWI/SNF and AR signaling. Strikingly, there is no understanding as to means by which BAF57 influences SWI/SNF activity (in any tissue) under conditions of tumorigenesis or homeostasis. Here, we will use novel genetic models of BAF57 depletion to delineate the molecular impact of BAF57 on SWI/SNF assembly, androgen-dependent AR cistromes, and prostate development (Aim 1). Second, our data indicate that BAF57 is significantly deregulated in high-grade PCa and CRPC. New models mimicking this event revealed a role for BAF57 in promoting for castration-resistant AR signaling. As AR binds to and modulates differential targets in CRPC, it is essential to assess the impact of tumor-associated BAF57 deregulation on the AR cistrome, the consequence for transcriptional regulation, and the clinical relevance of these observations (Aim 2). Third, tumor-associated BAF57 deregulation was predominant in lymph node deposits of CPRC, and deregulation of BAF57 in cells derived from lymph node metastases rendered cells resistant to androgen ablation in vitro. Thus, it is critical to challenge the in vivo consequence of tumor- associated BAF57 deregulation on tumor aggressiveness, lymph node metastasis, and therapy-resistance (Aim 3). Together, these novel aims will illuminate the means by which BAF57 influences SWI/SNF signaling and AR function, assess the in vivo consequence of both events, and define the consequence of tumor-associated BAF57 deregulation on disease progression.
There is a significant need to understand the mechanisms that lead to prostate cancer development and that promote lethal, castration-resistant tumor growth. Our data show that dysregulation of BAF57, a subunit of selected SWI/SNF chromatin remodeling complexes, promotes phenotypes associated with lethal disease. The studies here will challenge this concept using novel in vivo models, will provide molecular insight into the cellular and clinical consequence of BAF57 dysregulation, and have the potential for rapidly translatable outcomes to improve prostate cancer management.
|Hussain, Maha; Daignault-Newton, Stephanie; Twardowski, Przemyslaw W et al. (2018) Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol 36:991-999|
|Shafi, Ayesha A; Schiewer, Matthew J; de Leeuw, Renée et al. (2018) Patient-derived Models Reveal Impact of the Tumor Microenvironment on Therapeutic Response. Eur Urol Oncol 1:325-337|
|de Leeuw, Renée; McNair, Christopher; Schiewer, Matthew J et al. (2018) MAPK Reliance via Acquired CDK4/6 Inhibitor Resistance in Cancer. Clin Cancer Res 24:4201-4214|
|McNair, Christopher; Xu, Kexin; Mandigo, Amy C et al. (2018) Differential impact of RB status on E2F1 reprogramming in human cancer. J Clin Invest 128:341-358|
|Thomas, Jeffrey D; Longen, Charles G; Oyer, Halley M et al. (2017) Sigma1 Targeting to Suppress Aberrant Androgen Receptor Signaling in Prostate Cancer. Cancer Res 77:2439-2452|
|McNair, C; Urbanucci, A; Comstock, C E S et al. (2017) Cell cycle-coupled expansion of AR activity promotes cancer progression. Oncogene 36:1655-1668|
|Urbanucci, Alfonso; Barfeld, Stefan J; Kytölä, Ville et al. (2017) Androgen Receptor Deregulation Drives Bromodomain-Mediated Chromatin Alterations in Prostate Cancer. Cell Rep 19:2045-2059|
|Schiewer, Matthew J; Knudsen, Karen E (2016) Linking DNA Damage and Hormone Signaling Pathways in Cancer. Trends Endocrinol Metab 27:216-225|
|Goodwin, Jonathan F; Kothari, Vishal; Drake, Justin M et al. (2015) DNA-PKcs-Mediated Transcriptional Regulation Drives Prostate Cancer Progression and Metastasis. Cancer Cell 28:97-113|
|de Leeuw, Renée; Berman-Booty, Lisa D; Schiewer, Matthew J et al. (2015) Novel actions of next-generation taxanes benefit advanced stages of prostate cancer. Clin Cancer Res 21:795-807|
Showing the most recent 10 out of 22 publications